# Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer

> **NCT00791778** · PHASE2 · COMPLETED · sponsor: **Bayer** · enrollment: 246 (actual)

## Conditions studied

- Ovarian Neoplasms

## Interventions

- **DRUG:** Sorafenib (Nexavar, BAY43-9006)
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00791778
- **Lead sponsor:** Bayer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-11
- **Primary completion:** 2011-07
- **Final completion:** 2012-12
- **Target enrollment:** 246 (ACTUAL)
- **Last updated:** 2015-09-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00791778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00791778, "Comparison of Nexavar/Placebo as Maintenance Therapy for Patients With Advanced Ovarian or Primary Peritoneal Cancer". Retrieved via AI Analytics 2026-06-13 from https://api.ai-analytics.org/clinical/NCT00791778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*